Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1531 to 1540 of 2587 total matches.
Clozapine for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jan 12, 1990 (Issue 809)
blockade,
clozapine has serotonergic, adrenergic, histaminergic (H
1
) and cholinergic blocking activity ...
Clozapine (Clozaril - Sandoz), a dibenzodiazepine antipsychotic drug that has been available in Europe for many years, was recently approved for marketing by the US Food and Drug Administration. Because of its toxicity, the labeling for clozapine recommends using the drug only for schizophrenic patients who have not responded adequately to standard antipsychotic drugs or have had intolerable adverse effects.
Prevention And Treatment of Cholera
The Medical Letter on Drugs and Therapeutics • Nov 15, 1991 (Issue 857)
infection is less than 1%. Two types of
V. cholera are pathogenic: the classical biotype, which causes ...
Almost 300,000 cases of epidemic cholera have occurred in the Western Hemisphere in 1991, mostly in South and Central America (Morbid Mortal Weekly Rep, 40:562, Aug 16, 1991). The few US cases caused by the epidemic strain have been in returning travelers or associated with contaminated food they brought back illicitly, with no secondary spread to date.
Topical Drugs for Aging Skin
The Medical Letter on Drugs and Therapeutics • Aug 15, 1997 (Issue 1007)
approved by the FDA only for treatment of acne in concentrations ranging from 0.025% to 0.1% (Retin ...
Topical tretinoin (all-trans-retinoic acid) has been used for years to treat skin damaged by chronic exposure to the sun (Medical Letter, 34:28, 1992). First approved by the FDA only for treatment of acne in concentrations ranging from 0.025% to 0.1% (Retin-A, and others), it has now been approved as an 0.05% formulation in an emollient cream base (Renova) for topical treatment of photodamaged skin. In recent years, alpha-hydroxy acids incorporated in some cosmetics have also been promoted as effective in improving the appearance of aging skin.
Orlistat for Obesity
The Medical Letter on Drugs and Therapeutics • Jun 18, 1999 (Issue 1055)
with placebo. In the second year, patients who stayed on the drug
regained 1.5 to 3 kg, compared to a 4- to 6 ...
Orlistat, a lipase inhibitor that decreases absorption of fat from the gastrointestinal tract, is now available for treatment of obesity.
Spironolactone for Heart Failure
The Medical Letter on Drugs and Therapeutics • Sep 10, 1999 (Issue 1061)
, Cardiovasc Res, 35:30, 1997; KT Weber and D Villarreal, Basic Res Cardiol, 87 suppl 1:291,
1992). The drug ...
Spironolactone, an aldosterone receptor antagonist, has been FDA-approved for many years for treatment of edema, hypertension and primary hyperaldosteronism. Recently, it was reported to improve morbidity and mortality in patients with severe heart failure.
Entacapone for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jan 24, 2000 (Issue 1070)
found that entacapone compared to placebo increased "on"
time by an average of 1.4 hours, decreased ...
Entacapone (Comtan), a catechol-O-methyltransferase (COMT) inhibitor, has been approved by the FDA for adjunctive use with levodopa/carbidopa in patients with Parkinson's disease who have end-of-dose "wearing off"symptoms.
Exemestane For Advanced Breast Cancer
The Medical Letter on Drugs and Therapeutics • Apr 17, 2000 (Issue 1076)
inhibition of the enzyme. Exemestane (6-methylenandrosta-1,4-diene-3,17-dione), a derivative ...
The FDA has approved exemestane, an aromatase inhibitor, for the treatment of postmenopausal women with advanced breast cancer that has progressed during treatment with tamoxifen.
Photodynamic Therapy With Verteporfin (Visudyne) For Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Sep 04, 2000 (Issue 1086)
, has been reported in 1% to 4% of patients. Infusion-related back pain has occurred. Photosensitivity reactions ...
Photodynamic therapy with verteporfin (Visudyne--CIVA Vision), an injectable drug, is now being used for treatment of age-related macular degeneration. The drug is a benzoporphyrin derivative that, when activated by light in the presence of oxygen, generates highly reactive radicals that damage neovascular endorthelium and occlude the vessels.
Oxycodone OxyContin
The Medical Letter on Drugs and Therapeutics • Sep 17, 2001 (Issue 1113)
to morphine has ranged from 0.7 to 1.5. Parenteral oxycodone is 10 to
12 times as potent as codeine. Oral ...
Recent reports of inappropriate use and diversion of OxyContin tablets have prompted Purdue Pharma to include a "Black Box Warning"in the product labeling to call attention to the potential for abuse and to reinforce the FDA-approved indication "...for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time..."
Arrhythmias From Droperidol?
The Medical Letter on Drugs and Therapeutics • Jun 10, 2002 (Issue 1132)
anesthesiologists consider droperidol in doses of 0.625-1.25 mg IV
the drug of choice for patients at high risk ...
The FDA has added a "black box" warning about the risks of QT prolongation and the potentially fatal torsades de pointes (TdP) ventricular tachycardia to the labeling of droperidol (Inapsine - Akorn), an antiemetic used mostly in anesthesia. The Canadian Health Protection Branch has issued a similar warning. Some anesthesiologists have written to The Medical Letter to express their displeasure with these warnings.